Retatrutide vs. Semaglutide vs. Tirzepatide: Comparison for Metabolic Research

Three peptides currently dominate research in metabolism and energy regulation: Semaglutide, Tirzepatide, and Retatrutide. All three act on the incretin system, but with significantly distinct action profiles.

This comparison gathers what scientific literature has documented about each, with the aim of guiding researchers on the relevant differences between these compounds.

Context: The Incretin System

Incretins are gastrointestinal hormones that enhance insulin secretion after food intake. The two main incretin receptors are: GLP-1R (stimulates insulin secretion, suppresses glucagon, delays gastric emptying) and GIPR (complements GLP-1R in insulin secretion; effects on lipid and bone metabolism). A third receptor, the glucagon receptor (GCGR), stimulates hepatic gluconeogenesis and also increases energy expenditure when activated in the context of simultaneous GLP-1 agonism.

Semaglutide — The Established GLP-1 Agonist

Mechanism

Selective GLP-1 receptor agonist. An analog of native GLP-1 with amino acid substitutions and a C-18 fatty acid chain that allows albumin binding and prolongs its half-life to ~7 days.

Clinical research data

STEP 1 study (Wilding et al., NEJM 2021): average weight reduction of ~15% in 68 weeks. The most studied molecule in the group (most available literature). Well-characterized dose-response. Comparative reference in metabolic studies.

Tirzepatide — The Dual GLP-1/GIP Agonist

Mechanism

Dual agonist that simultaneously activates GLP-1R and GIPR. GIPR activation adds complementary effects on lipid metabolism and amplifies the insulinotropic response of GLP-1.

Clinical research data

SURMOUNT-1 study (Jastreboff et al., NEJM 2022): weight reduction of ~20.9% in 72 weeks with a 15 mg dose. Superior effects to Semaglutide alone in head-to-head studies (SURPASS-2). Ideal model for studying GLP-1R/GIPR interaction with robust Phase 3 clinical data.

Retatrutide — The Triple Agonist

Mechanism

Triple agonist: GLP-1R + GIPR + GCGR. The glucagon agonism component adds a new dimension: increased resting energy expenditure and greater fatty acid oxidation, without the hyperglycemic effects that glucagon alone would have (mitigated by simultaneous GLP-1 agonism).

Clinical research data

Phase 2 study (Jastreboff et al., NEJM 2023): weight reduction of ~17.5% in 24 weeks and projected >22% at 48 weeks. Greater weight reduction than Semaglutide and comparable or superior to Tirzepatide in long-term projection. Phase 3 ongoing. Preliminary data show a superior profile in fat mass vs. lean mass reduction.

Comparative Table

Semaglutide: GLP-1 Receptor | Weight reduction ~15% (48 weeks) | Very extensive literature | Approved phase* | Moderate energy expenditure effect | Available at MVLabs ✓

Tirzepatide: GLP-1 + GIP | ~21% | Extensive literature | Approved phase* | Moderate-high energy expenditure | Available at MVLabs ✓

Retatrutide: GLP-1 + GIP + Glucagon | ~22%+ | Growing literature | Phase 3 | High energy expenditure | Available at MVLabs ✓

*Approved as a drug in some countries; available at MVLabs exclusively for scientific research.

Which one to choose for research?

Depends on the research objective:

• Studies on isolated GLP-1 agonism → Semaglutide (more literature, better characterized)
• Studies on GLP-1/GIP interaction → Tirzepatide
• Studies on triple agonism or energy expenditure → Retatrutide
• Comparisons between generations of compounds → All three

Purchase in Mexico for Research

MVLabs offers all three compounds with ≥99% HPLC purity, lyophilized, with authenticity verification by QR code. Discreet shipping throughout Mexico in 3–5 business days.

Legal Notice: All MVLabs products are exclusively for use in scientific research. Not for human or animal consumption.

MVLabs — Research Peptides ≥99% in Mexico | mvlabs.mx